Central nervous system cancers, version 1.2017 featured updates to the NCCN guidelines

Louis Burt Nabors, Jana Portnow, Mario Ammirati, Joachim Baehring, Henry Brem, Nicholas Butowski, Robert A. Fenstermaker, Peter Forsyth, Jona Hattangadi-Gluth, Matthias Holdhoff, Steven Howard, Larry Junck, Thomas Kaley, Priya Kumthekar, Jay S. Loeffler, Paul L. Moots, Maciej M. Mrugala, Seema Nagpal, Manjari Pandey, Ian ParneyKatherine Peters, Vinay K. Puduvalli, John Ragsdale, Jason Rockhill, Lisa Rogers, Chad Rusthoven, Nicole Shonka, Dennis C. Shrieve, Allen K. Sills, Lode J. Swinnen, Christina Tsien, Stephanie Weiss, Patrick Yung Wen, Nicole Willmarth, Mary Anne Bergman, Anita Engh

    Research output: Contribution to journalArticlepeer-review

    107 Scopus citations

    Abstract

    For many years, the diagnosis and classification of gliomas have been based on histology. Although studies including large populations of patients demonstrated the prognostic value of histologic phenotype, variability in outcomes within histologic groups limited the utility of this system. Nonetheless, histology was the only proven and widely accessible tool available at the time, thus it was used for clinical trial entry criteria, and therefore determined the recommended treatment options. Research to identify molecular changes that underlie glioma progression has led to the discovery of molecular features that have greater diagnostic and prognostic value than histology. Analyses of these molecular markers across populations from randomized clinical trials have shown that some of these markers are also predictive of response to specific types of treatment, which has prompted significant changes to the recommended treatment options for grade III (anaplastic) gliomas.

    Original languageEnglish
    Pages (from-to)1331-1345
    Number of pages15
    JournalJNCCN Journal of the National Comprehensive Cancer Network
    Volume15
    Issue number11
    DOIs
    StatePublished - Nov 1 2017

    Fingerprint

    Dive into the research topics of 'Central nervous system cancers, version 1.2017 featured updates to the NCCN guidelines'. Together they form a unique fingerprint.

    Cite this